Kezdőlap・Részvénylista・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Lezárt

SzektorEgészségügy

213.34

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

207.67

Maximum

215.94

Fő mutatók
By Trading Economics
Bevétel	13M -51M
Értékesítés	27M 218M
Egy részvényre jutó nyereség	-0.99
Profit margin	-23.498
Munkavállalók	1,220
EBITDA	11M -50M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+36.19% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 2.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	507M 11B
Előző nyitás	213.34
Előző zárás	213.34

Hangulat hírek alapján

By Acuity

16%

84%

35 / 340 Rangsor szerint Healthcare

Axsome Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

2026. aug. 13. 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

2026. aug. 12. 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

2026. aug. 11. 19:45 UTC

Social Media

News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

2026. aug. 10. 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

2026. aug. 7. 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

2026. aug. 6. 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

2026. aug. 5. 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

2026. aug. 4. 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

2026. aug. 3. 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

2026. júl. 31. 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

2026. júl. 30. 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

2026. júl. 29. 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

2026. júl. 28. 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

2026. júl. 27. 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

2026. júl. 24. 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

2026. júl. 22. 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

2026. júl. 21. 19:51 UTC

Social Media

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

2026. júl. 20. 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Társak összehasonlítása

Árváltozás

Axsome Therapeutics Inc Előrejelzés

Célár

By TipRanks

36.19% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 291 USD 36.19%

Magas 380 USD

Alacsony 251 USD

13 Wall Street elemző 12 hónapos célárain alapulva a(z)Axsome Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

13 ratings

Vétel

Tartás

Eladás

13 Wall Street elemző célárain alapulva a(z)Axsome Therapeutics Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

35 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.